Table of Contents Table of Contents
Previous Page  16 / 154 Next Page
Show Menu
Previous Page 16 / 154 Next Page
Page Background

Speaker’s Biographies

Professor Markopoulos has participated in over 400 National and International congresses and meetings, giving lectures

as invited speaker (>100 times in International meetings) or presenting research data (>250 oral/poster presentations),

awarded on 15 occasions. He has himself organized a large number of national and international congresses, meetings

and postgraduate courses on breast cancer over the last 30 years. During the last 20 consecutive years he organizes in

Athens the 2-day Annual National Meeting on the Advances in Breast Cancer Care.

Christophe Massard

DITEP, Villejuif, France

General background:

Christophe Massard, MD, PhD, medical oncologist, senior consultant at Drug Development department and Department

of Medical Oncology, joined the faculty in 2006. He is Head in patient Unit of DDD. He received his medical degree

from PARIS XI University. He completed his residency training in Paris Hospital, followed by his fellowship in medical

oncology at Gustave Roussy. Dr Massard is member of ESMO, ASCO, AACR. Dr Massard is board-certified in Medical

Oncology. His research interests include early clinical trials, precision medicine, GU cancers, and circulating biomarkers.

Phase I expertise:

Recent phase I publications:

Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T, Mattila L,

Aspegren J, Vuorela A, Langmuir P, Mustonen M; ARADES study group. Activity and safety of ODM-201 in patients

with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and

randomised phase 2 dose expansion trial. Lancet Oncol. 2014 Aug;15(9):975-85. doi: 10.1016/S1470-2045(14)70240-2.

Paoletti X, Le Tourneau C, Verweij J, Siu LL, Seymour L, Postel-Vinay S, Collette L, Rizzo E, Ivy P, Olmos D, Massard C,

Lacombe D, Kaye SB, Soria JC. Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results

of a DLT-TARGETT international survey. Eur J Cancer. 2014 Aug;50(12):2050-6. doi: 10.1016/j.ejca.2014.04.030.

Hollebecque A, Massard C, Soria JC. Implementing precision medicine initiatives in the clinic: a new paradigm in drug

development. Curr Opin Oncol. 2014 May;26(3):340-6. doi: 10.1097/CCO.0000000000000077. Review.

Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS, Massard

C. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after

docetaxel and enzalutamide (MDV3100). Ann Oncol. 2013 Jul;24(7):1807-12. doi: 10.1093/annonc/mdt136.

Massard C, Margetts J, Amellal N, Drew Y, Bahleda R, Stephens P, Armand JP, Calvert H, Soria JC, Coronado C,

Kahatt C, Alfaro V, Siguero M, Fernández-Teruel C, Plummer R. Phase I study of PM00104 (Zalypsis


) administered

as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors. Invest New Drugs. 2013

Jun;31(3):623-30. doi: 10.1007/s10637-012-9843-5.

Speaker Abstract(s): S37, S38

Francesco Merli

Hematology Unit


Oncology and Advanced Technologies





I was born on the 26


December 1959 in Reggio Emilia (Italy), where I still live.

Work experience:

I graduated in 1987 in Medicine at the University of Modena, and in 1990 I achieved the specialization in Haematology

at the University of Modena.

I worked as Internal Medicine physician in General Medicine Unit at the Arcispedale Santa Maria Nuova, Reggio Emilia,

from January 1991 to September 1997. In 1993 I spent one year to Ampasimanjeva Hospital in Magadascar where I

worked as physician and I coordinated the Medicine Unit. In 1995 I spent a training period for bone marrow autologous

and allogeneic transplant at the Haematology Division II at the San Martino Hospital in Genova for two months.

From October 1997 I worked in the Division of Haematology in Reggio Emilia. In 2001 I spent a training period at the

Lymphoma and Myeloma Departement to MD Anderson Cancer Center in Houston (Texas – USA) for two months.

In October 2009 I became the Head of Hematology Unit at the Arcispedale Santa Maria Nuova IRCCS in Reggio Emilia.

Scientific activities and publications:

My scientific activities are mainly focused on clinical therapeutic research on lymphomas.

In October 2002 I have been acknowledged with a “High Specialization for diagnosis and Therapy of Lymphoma” job degree.

Since 2002 I am coordinating the “Lymphoma Project” that aimes to update every healt-operator in Arcispedale Santa

Maria Nuova that works in “Diagnosis and Therapy of Lymphoma” field, through foreign stages and meeting/seminars.

In 2007 the program was updated to the “Corporate Project Linfocare 2007-2011”, that had as aim the clinical and

biological research in Lymphoma, and that I am still coordinating.

I am founding member and member of the Directive board of Italian Lymphoma Foundation (Fondazione Italiana

Linfomi_FIL ONLUS), that is a non-profit organization that coordinates and carries out scientific research projects for

the treatment of lymphomas and lymphoproliferative diseases. This association works through appropriate Scientific

Committees of experts concerned with evaluating proposals for clinical studies and provide guidance on treatment or

on diagnostic techniques for different types of lymphoma. Currently, I coordinate the Elderly Lymphomas Scientific


My research interests include elderly patients with lymphomas, hodgkin lymphoma and the use of FDG-PET in

lymphomas. I’m involved in many clinical studies as Principal Investigator.